Tecnobios Procreazione, Centre for Reproductive Health, Via Dante 15, I-40125 Bologna, Italy.
Reprod Biomed Online. 2009 Oct;19(4):604-9. doi: 10.1016/j.rbmo.2009.06.009.
Two hundred women aged between 28 and 43 years, with infertility from tubal, male, endometriosis or unexplained factor were randomly allocated into treatment (100 patients) and control (100 patients) groups. On the day after oocyte retrieval, each patient began supplementation with progesterone 8% vaginal gel, once daily. The patients in the treatment group received a single oral dose of 10 mg of the non-steroidal anti-inflammatory drug piroxicam 1-2 h before embryo transfer. No statistically significant difference was found between the two groups in any of the analysed endpoints. The rate of positive beta-human chorionic gonadotrophin test per transfer was 37% in the women treated with piroxicam and 47% in controls. The clinical pregnancy rate per transfer and implantation rate were 34% and 19.2% with piroxicam, 38% and 21.9% in controls. The miscarriage rate was 11.8% and 13.2%. No beneficial effect of piroxicam on pregnancy rates was found evaluating either different infertility causes or different ages. This study shows that the administration of a single dose of piroxicam before embryo transfer has no additional effect on pregnancy outcome in patients receiving adequate doses of progesterone for luteal phase supplementation after IVF or ICSI.
两百名年龄在 28 至 43 岁之间的女性，因输卵管、男性、子宫内膜异位症或不明原因而不孕，被随机分配到治疗组（100 名患者）和对照组（100 名患者）。取卵后第二天，每位患者开始每天一次阴道补充 8%的孕酮凝胶。治疗组患者在胚胎移植前 1-2 小时口服 10 毫克非甾体抗炎药吡罗昔康。在任何分析终点，两组之间均无统计学差异。接受吡罗昔康治疗的患者每转移的阳性β-人绒毛膜促性腺激素测试率为 37%，对照组为 47%。每转移的临床妊娠率和着床率分别为吡罗昔康组 34%和 19.2%，对照组为 38%和 21.9%。流产率分别为 11.8%和 13.2%。评估不同不孕原因或不同年龄时，均未发现吡罗昔康对妊娠率有有益影响。本研究表明，在接受 IVF 或 ICSI 后黄体期补充足够剂量孕酮的患者中，胚胎移植前给予单次剂量吡罗昔康对妊娠结局没有额外影响。
